Journal article
Infliximab therapy in refractory sarcoidosis: a multicenter real-world analysis
Abstract
BackgroundInfliximab is a monoclonal antibody that binds and neutralizes circulating tumor necrosis factor-alpha, a key inflammatory cytokine in the pathophysiology of sarcoidosis. Despite the paucity of randomized clinical trials, infliximab is often considered a therapeutic option for refractory disease. Our study aimed to investigate the effectiveness of infliximab in patients with refractory sarcoidosis.MethodsSarcoidosis patients from …
Authors
Sakkat A; Cox G; Khalidi N; Larche M; Beattie K; Renzoni EA; Morar N; Kouranos V; Kolb M; Hambly N
Journal
Respiratory Research, Vol. 23, No. 1,
Publisher
Springer Nature
Publication Date
December 2022
DOI
10.1186/s12931-022-01971-5
ISSN
1465-9921